Skip to main content

IGF-1 LR3 vs DSIP

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

IGF-1 LR3

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with extended half-life and enhanced potency. The modifications prevent binding to IGF binding proteins, increasing bioavailability.

Full details →

DSIP

Delta Sleep-Inducing Peptide is a neuropeptide that promotes delta wave sleep, the deepest and most restorative phase of the sleep cycle.

Full details →

Side-by-Side Comparison

AspectIGF-1 LR3DSIP
MechanismBinds to IGF-1 receptors to promote protein synthesis, muscle growth, and fat metabolism. The LR3 modification (13 amino acid extension and arginine substitution) extends half-life from minutes to 20-30 hours.Modulates sleep-wake cycles by affecting sleep spindles and delta rhythms. May also influence stress hormones and have analgesic properties.
Typical DosageResearch protocols typically use 20-100mcg daily, often divided into multiple injections or administered bilaterally to target muscles.Typical dosing: 100-300mcg administered 30 minutes before sleep. Some protocols use it cyclically.
AdministrationIntramuscular injection (site-specific growth) or subcutaneous for systemic effects. Often cycled 4-6 weeks on, equal time off.Subcutaneous or intramuscular injection before bedtime. Some users report better results with cyclical use.
Side EffectsHypoglycemia, joint pain, water retention, potential jaw/hand growth with extended use, and injection site reactions.May cause grogginess upon waking, vivid dreams, or temporary headaches.
Best For

What They Have in Common

Both IGF-1 LR3 and DSIP are commonly used for:

Key Differences

Unique to IGF-1 LR3:

Unique to DSIP:

Detailed Analysis

Both DSIP and IGF-1 LR3 are commonly used for Recovery & Healing.

Which Should You Choose?

Both peptides have similar evidence levels for their shared goals. Your choice may depend on specific use case, availability, or personal response.

Ready to Learn More?